Challenges in patient-physician communication during limited time appointments in Parkinson’s disease
Objective: Our aim is to analyze challenges in patient-physician communication during limited time appointments in Parkinson’s disease (PD). Background: Due to limited number of movement…Parkinson’s Progression Markers Initiative (PPMI) prioritizes enrollment of individuals from diverse and underrepresented populations
Objective: To describe the goals and Year 1 initiatives of PPMI Diversity, Equity, and Inclusion (DEI) taskforce Background: Clinical trials under-enroll people with Parkinson’s disease…Deep brain stimulation impacts functional brain connectivity in Parkinson’s disease.
Objective: Deep-brain stimulation (DBS) became a successful method to treat Parkinson’s disease (PD), particularly with stimulating the subthalamic nucleus (STN-DBS), although the precise mechanisms mediating…Efficacy of a four-strain probiotic on gut dysbiosis, motor and non-motor symptoms in Parkinson`s disease: a multicentre randomised controlled trial
Objective: To evaluate the effect of a four-strain probiotic (Lacticaseibacillus rhamnosus, Enterococcus faecium, Lactobacillus acidophilus, Lactiplantibacillus plantarum) on gut microbiota composition, motor and non-motor symptoms…Clinical characterization of Parkinson’s disease patients with LRRK2 mutation: Insights from a Portuguese reference center
Objective: This study aims to provide a clinical characterization of Parkinson's disease (PD) patients with LRRK2 mutations, who are being treated at a Portuguese reference…Understanding rehabilitation care utilization in Parkinson’s disease
Objective: The aim of our study was to examine experiences with rehabilitation services by people with Parkinson’s disease (PD) and their care partners (CP). Background:…Effect of multi-strain probiotics on gut microbiome and metabolites in Parkinson’s Disease
Objective: We investigated the effects of multi-strain probiotics administration on gut microbiome and metabolites, and markers of intestinal permeability and inflammation. Background: Probiotics have been…Anle138b-P1-02: A randomised, double-blinded, placebo-controlled phase 1b study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of the oligomer modulator anle138b in Parkinson´s disease
Objective: To present first-in-patient data of the oligomer modulator anle138b (TEV-56286, emrusolmin) in patients with Parkinson’s disease (PD). Background: Synucleinopathies such as PD and Multiple…Short and long-term effects of deep brain stimulation on cognition in Parkinson’s disease
Objective: To evaluate long-term effects of subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson’s disease (PD) on cognition. Background: Cognitive changes are common among patients…Local field potentials in the subthalamic nucleus of patients with Parkinson’s disease – Effect of the deep brain stimulation
Objective: To obtain knowledge that would lead to the usage of local field potentials (LFP) in the deep brain stimulation therapy (DBS). Background: The LFP…
- « Previous Page
- 1
- …
- 169
- 170
- 171
- 172
- 173
- …
- 338
- Next Page »